<p>With the expected worldwide rise in all-cause dementia to approximately 152.8 million by the year 2050 and the potential for disease-modifying therapies such as anti-amyloid monoclonal antibodies, there will be an increased demand on neurologists and memory clinics to rapidly identify and stage pati</p>